Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1992 1
1996 1
1997 1
2000 1
2003 2
2004 1
2005 2
2006 3
2007 2
2008 3
2009 4
2010 3
2011 3
2012 3
2014 2
2017 2
2018 1
2020 1
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis.
Pender MP, Csurhes PA, Smith C, Douglas NL, Neller MA, Matthews KK, Beagley L, Rehan S, Crooks P, Hopkins TJ, Blum S, Green KA, Ioannides ZA, Swayne A, Aftab BT, Hooper KD, Burrows SR, Thompson KM, Coulthard A, Khanna R. Pender MP, et al. Among authors: csurhes pa. JCI Insight. 2018 Nov 15;3(22):e124714. doi: 10.1172/jci.insight.124714. JCI Insight. 2018. PMID: 30429369 Free PMC article. Clinical Trial.
Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis.
Pender MP, Csurhes PA, Smith C, Douglas NL, Neller MA, Matthews KK, Beagley L, Rehan S, Crooks P, Hopkins TJ, Blum S, Green KA, Ioannides ZA, Swayne A, Aftab BT, Hooper KD, Burrows SR, Thompson KM, Coulthard A, Khanna R. Pender MP, et al. Among authors: csurhes pa. JCI Insight. 2020 Oct 15;5(20):e144624. doi: 10.1172/jci.insight.144624. JCI Insight. 2020. PMID: 33055421 Free PMC article. No abstract available.
Sustained Clinical Improvement in a Subset of Patients With Progressive Multiple Sclerosis Treated With Epstein-Barr Virus-Specific T Cell Therapy.
Ioannides ZA, Csurhes PA, Douglas NL, Mackenroth G, Swayne A, Thompson KM, Hopkins TJ, Green KA, Blum S, Hooper KD, Wyssusek KH, Coulthard A, Pender MP. Ioannides ZA, et al. Among authors: csurhes pa. Front Neurol. 2021 Mar 15;12:652811. doi: 10.3389/fneur.2021.652811. eCollection 2021. Front Neurol. 2021. PMID: 33790852 Free PMC article.
Strains of Epstein-Barr virus infecting multiple sclerosis patients.
Brennan RM, Burrows JM, Bell MJ, Bromham L, Csurhes PA, Lenarczyk A, Sverndal J, Klintenstedt J, Pender MP, Burrows SR. Brennan RM, et al. Among authors: csurhes pa. Mult Scler. 2010 Jun;16(6):643-51. doi: 10.1177/1352458510364537. Epub 2010 Mar 29. Mult Scler. 2010. PMID: 20350958
Correlations between macrophage/microglial activation marker sTREM-2 and measures of T-cell activation, neuroaxonal damage and disease severity in multiple sclerosis.
Ioannides ZA, Csurhes PA, Swayne A, Foubert P, Aftab BT, Pender MP. Ioannides ZA, et al. Among authors: csurhes pa. Mult Scler J Exp Transl Clin. 2021 Jun 3;7(2):20552173211019772. doi: 10.1177/20552173211019772. eCollection 2021 Apr-Jun. Mult Scler J Exp Transl Clin. 2021. PMID: 34158970 Free PMC article.
35 results